



Unravelling Cancer Mechanism and Developing Novel Therapeutics: An Urgent Need to Treat Cancer

Guest Editors:

Dr. Rajesh Singh

1. Department of Microbiology,
Immunology, and Biochemistry,
Morehouse School of Medicine,
Atlanta, GA 30310, USA
2. Cancer Health Equity Institute,
Morehouse School of Medicine,
Atlanta, GA 30310, USA

Dr. Santosh Kumar Singh

Department of Microbiology,
Biochemistry & Immunology,
Morehouse School of Medicine,
Atlanta, GA 30310, USA

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Over several decades, cancer has been a rapidly growing health concern throughout the world. Many cancer screening programs are widely being implemented in high- and middle-income countries to reduce cancer incidence and mortality. However, the yearly rise in cases is disappointing considering the extensive use of various therapeutic approaches today. Emerging evidence suggests that drug resistance and relapse also represent significant issues during treatment. Therefore, no single breakthrough can cure cancer; in lieu, cumulative knowledge of complex underlying mechanisms could reduce many related deaths. Thus, understanding signaling pathways and developing novel targeted techniques, including molecular, biochemical, immunological, and nanotherapy, may give hope to clinicians searching for new targets for treatment.

To address these challenges, this Special Issue aims to present novel targeted therapies and their underlying cancer mechanism, including but not limited to natural compound combination therapy, chemotherapy, Immunotherapy, and nanotherapy. We welcome you to submit the original research and review articles on the latest progress in these topics.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI